Corporate Presentation September 2020 1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and "our

0 Exhibit 99.1 Corporate Presentation September 20200 Exhibit 99.1

Corporate Presentation September 2020

1 Forward-Looking Statements and Other Important Cautions / Industry and

Market Data Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and "our" refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare

Public Acquisition Corp.), a Delaware corporation, and its subsidiaries. References in this presentation to the "Business Combination" refer to the consummation of the transactions contemplated by that certain Agreement and Plan of

Merger, dated as of August 17, 2018, which transactions were consummated on December 10, 2018. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking

statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target,"

"anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or

that are not statements of historical matters. Such forward-looking statements include statements relating to the Company's expected revenue for fiscal 2020 and the breakdown of such revenue in both its Advanced Wound Care and Surgical &

Sports Medicine categories as well as the estimated revenue contribution of its PuraPly products and non-PuraPly products and statements related to ongoing clinical trials and the expected launch dates for new products. Forward- looking statements

with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results

or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the Company has incurred significant losses since inception and anticipates that it will

incur substantial losses for the foreseeable future; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause

the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must

convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the impact of any

changes to the reimbursement levels for the Company's products and the impact to the Company of the loss of preferred "pass through" status for PuraPly AM and PuraPly on October 1, 2020; (7) the Company's ability to maintain

compliance with applicable Nasdaq listing standards; (8) changes in applicable laws or regulations; (9) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (10) the Company's

ability to complete the relaunch of Affinity and to maintain production in sufficient quantities to meet demand; and (11) other risks and uncertainties described under the caption Risk Factors in Item 1A (Risk Factors) of the Company's Form

10-K for the year ended December 31, 2019 and in subsequent periodic filings with the SEC including risks related to the coronavirus (COVID-19) pandemic. You are cautioned not to place undue reliance upon any forward-looking statements, which speak

only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as

required by applicable securities laws. Unless otherwise noted, the forecasted industry and market data contained herein are based upon management estimates and industry and market publications and surveys. The information from industry and market

publications has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. The Company has not independently verified any of the data from third-party sources,

nor has the Company ascertained the underlying economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used herein, the Company makes no representation or warranty with respect to the accuracy of

such information. 11 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms "Organogenesis," "Company," "we," "us" and

"our" refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation, and its subsidiaries. References in this presentation to the "Business Combination" refer to

the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 17, 2018, which transactions were consummated on December 10, 2018. This presentation contains forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as "forecast,"

"intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar

expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company's expected revenue for fiscal 2020 and the breakdown of

such revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories as well as the estimated revenue contribution of its PuraPly products and non-PuraPly products and statements related to ongoing clinical trials and the

expected launch dates for new products. Forward- looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and

unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the Company has incurred

significant losses since inception and anticipates that it will incur substantial losses for the foreseeable future; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and

financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively

compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability

to raise funds to expand its business; (6) the impact of any changes to the reimbursement levels for the Company's products and the impact to the Company of the loss of preferred "pass through" status for PuraPly AM and PuraPly on

October 1, 2020; (7) the Company's ability to maintain compliance with applicable Nasdaq listing standards; (8) changes in applicable laws or regulations; (9) the possibility that the Company may be adversely affected by other economic,

business, and/or competitive factors; (10) the Company's ability to complete the relaunch of Affinity and to maintain production in sufficient quantities to meet demand; and (11) other risks and uncertainties described under the caption Risk

Factors in Item 1A (Risk Factors) of the Company's Form 10-K for the year ended December 31, 2019 and in subsequent periodic filings with the SEC including risks related to the coronavirus (COVID-19) pandemic. You are cautioned not to place

undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a

result of new information, future events or otherwise, except as required by applicable securities laws. Unless otherwise noted, the forecasted industry and market data contained herein are based upon management estimates and industry and market

publications and surveys. The information from industry and market publications has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. The Company has not

independently verified any of the data from third-party sources, nor has the Company ascertained the underlying economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used herein, the Company

makes no representation or warranty with respect to the accuracy of such information. 1

2 Use of Non-GAAP Financial Measures This Company has presented the

following measures that are not measures of performance under accounting principles generally accepted in the United States ("GAAP"): EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are not measurements of our financial

performance under GAAP and these measures should not be considered as an alternative to net income, operating income or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities

(including net cash used in operating activities and purchases of property and equipment) as a measure of our liquidity. EBITDA as used herein is defined as net income (loss) attributable to Organogenesis Holdings Inc. before depreciation and

amortization, net interest expense and income taxes and the Company defines Adjusted EBITDA as EBITDA, further adjusted for the impact of certain items that the Company does not consider indicative of its core operating performance. These items may

include non- cash equity compensation, mark to market adjustments on the Company's warrant liabilities, change in fair value of interest rate swaps and its contingent asset and liabilities, write-off of deferred offering costs, merger

transaction costs related to the Business Combination, a loss on the extinguishment of debt, and other costs and expenses incurred not related to the Company's core operations. The Company presented Adjusted EBITDA in this presentation because

it is a key measure used by the Company's management and Board of Directors to understand and evaluate the Company's operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In

particular, the Company's management believes that the exclusion of certain items in calculating Adjusted EBITDA can produce a useful measure for period-to-period comparisons of the Company's business. The Company's management does not

consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. Other companies may calculate EBITDA, Adjusted EBITDA, and other non-GAAP measures differently, and therefore the

Company's EBITDA, Adjusted EBITDA, and other non-GAAP measures may not be directly comparable to similarly titled measures of other companies. A reconciliation of Non-GAAP measures used in this presentation to the most closely comparable GAAP

measure is set forth in the Appendix. There are a number of limitations related to the use of Adjusted EBITDA rather than net income (loss), which is the most directly comparable GAAP equivalent. Some of these limitations are: Adjusted

EBITDA excludes stock-based compensation expense, as stock-based compensation expense has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation

strategy; Adjusted EBITDA excludes depreciation and amortization expense and, although these are non-cash expenses, the assets being depreciated may have to be replaced in the future; Adjusted EBITDA excludes net interest expense, or

the cash requirements necessary to service interest, which reduces cash available to us; Adjusted EBITDA excludes the impact of the changes in the fair value of our warrant liability and our contingent consideration forfeiture asset;

Adjusted EBITDA excludes the write-off of deferred offering costs in connection with an abandoned public offering, as well as merger transaction costs, consisting primarily of legal and professional fees; Adjusted EBITDA excludes the loss of

extinguishment of debt, which is a non-cash loss related to the write-off of unamortized debt issuance costs upon repayment of affiliate and third-party debt, and related prepayment penalties; Adjusted EBITDA excludes the advisory, legal,

and professional fees incurred in connection with the warrant exchange transactions; Adjusted EBITDA excludes other costs and expenses incurred not related to operations; Adjusted EBITDA excludes income tax expense (benefit); and

Other companies, including companies in our industry, may calculate Adjusted EBITDA differently, which reduces its usefulness as a comparative measure. 22 Use of Non-GAAP Financial Measures This Company has presented the following measures

that are not measures of performance under accounting principles generally accepted in the United States ("GAAP"): EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are not measurements of our financial performance under GAAP and

these measures should not be considered as an alternative to net income, operating income or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities (including net cash used in

operating activities and purchases of property and equipment) as a measure of our liquidity. EBITDA as used herein is defined as net income (loss) attributable to Organogenesis Holdings Inc. before depreciation and amortization, net interest expense

and income taxes and the Company defines Adjusted EBITDA as EBITDA, further adjusted for the impact of certain items that the Company does not consider indicative of its core operating performance. These items may include non- cash equity

compensation, mark to market adjustments on the Company's warrant liabilities, change in fair value of interest rate swaps and its contingent asset and liabilities, write-off of deferred offering costs, merger transaction costs related to the

Business Combination, a loss on the extinguishment of debt, and other costs and expenses incurred not related to the Company's core operations. The Company presented Adjusted EBITDA in this presentation because it is a key measure used by the

Company's management and Board of Directors to understand and evaluate the Company's operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In particular, the Company's

management believes that the exclusion of certain items in calculating Adjusted EBITDA can produce a useful measure for period-to-period comparisons of the Company's business. The Company's management does not consider these non-GAAP

measures in isolation or as an alternative to financial measures determined in accordance with GAAP. Other companies may calculate EBITDA, Adjusted EBITDA, and other non-GAAP measures differently, and therefore the Company's EBITDA, Adjusted

EBITDA, and other non-GAAP measures may not be directly comparable to similarly titled measures of other companies. A reconciliation of Non-GAAP measures used in this presentation to the most closely comparable GAAP measure is set forth in the

Appendix. There are a number of limitations related to the use of Adjusted EBITDA rather than net income (loss), which is the most directly comparable GAAP equivalent. Some of these limitations are: Adjusted EBITDA excludes stock-based

compensation expense, as stock-based compensation expense has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; Adjusted

EBITDA excludes depreciation and amortization expense and, although these are non-cash expenses, the assets being depreciated may have to be replaced in the future; Adjusted EBITDA excludes net interest expense, or the cash requirements

necessary to service interest, which reduces cash available to us; Adjusted EBITDA excludes the impact of the changes in the fair value of our warrant liability and our contingent consideration forfeiture asset; Adjusted EBITDA

excludes the write-off of deferred offering costs in connection with an abandoned public offering, as well as merger transaction costs, consisting primarily of legal and professional fees; Adjusted EBITDA excludes the loss of extinguishment

of debt, which is a non-cash loss related to the write-off of unamortized debt issuance costs upon repayment of affiliate and third-party debt, and related prepayment penalties; Adjusted EBITDA excludes the advisory, legal, and professional

fees incurred in connection with the warrant exchange transactions; Adjusted EBITDA excludes other costs and expenses incurred not related to operations; Adjusted EBITDA excludes income tax expense (benefit); and Other

companies, including companies in our industry, may calculate Adjusted EBITDA differently, which reduces its usefulness as a comparative measure. 2

3 Key Company Highlights $8.9Bn+ $6Bn+ Attractive End Markets Advanced

Wound Care Surgical & Sports Medicine 1 Market (AWC) Market (S&SM) Differentiated and Comprehensive Suite of 2 Products Proven R&D Engine with Pipeline products recently launched or 7 expected to in next 2 years 3 Deep Pipeline Robust

Clinical Data 200+ 15 (1) Publications reviewing 4 Ongoing studies Supporting Products Organogenesis products ~285 Direct Sales Representatives 3,200+ 450k+ Established and Scalable Healthcare facilities Square feet across Infrastructure 5 (2) ~160

served in 2019 4 dedicated facilities Independent Agencies Growth Drivers: $270mm - Organic end market growth LTM 06/30/20A revenue Rapidly Scaling Business with - New product introductions 6 Multiple Levers for Growth - Manufacturing expansion

& efficiencies 71% (3) - M&A / in-licensing opportunities Gross margin Notes: 1. Includes studies yet to publish data and retrospective projects. 3 2. Number of facilities that have ordered products in 2019. 3. 12 months ended 6/30/20 gross

margin.3 Key Company Highlights $8.9Bn+ $6Bn+ Attractive End Markets Advanced Wound Care Surgical & Sports Medicine 1 Market (AWC) Market (S&SM) Differentiated and Comprehensive Suite of 2 Products Proven R&D Engine with Pipeline

products recently launched or 7 expected to in next 2 years 3 Deep Pipeline Robust Clinical Data 200+ 15 (1) Publications reviewing 4 Ongoing studies Supporting Products Organogenesis products ~285 Direct Sales Representatives 3,200+ 450k+

Established and Scalable Healthcare facilities Square feet across Infrastructure 5 (2) ~160 served in 2019 4 dedicated facilities Independent Agencies Growth Drivers: $270mm - Organic end market growth LTM 06/30/20A revenue Rapidly Scaling Business

with - New product introductions 6 Multiple Levers for Growth - Manufacturing expansion & efficiencies 71% (3) - M&A / in-licensing opportunities Gross margin Notes: 1. Includes studies yet to publish data and retrospective projects. 3 2.

Number of facilities that have ordered products in 2019. 3. 12 months ended 6/30/20 gross margin.

4 Experienced Leadership with Track Record of Execution Henry Hagopian

Gary Gillheeney, Sr Patrick Bilbo Brian Grow Antonio Montecalvo Lori Freedman Interim Chief Financial President & Chief Chief Operating Chief Commercial VP, Health Policy VP and Officer, VP Finance, Executive Officer Officer Officer and

Contracting General Counsel Treasurer 25+ years in senior 13 years at 26 years with 16 years with 17 years with 15+ years as public leadership positions in Organogenesis Organogenesis Organogenesis

Organogenesis company general both public and counsel and business Previously held 6 years experience of Previously held Previously spent 3 private organizations development executive controller and manager Provider

contracting management and years at Novartis / Served as President positions at CIRCOR with UnitedHealth and Most recently VP research positions at Innovex and 1 year at and CEO of International and 7 years public Corporate Affairs,

Hologic, Stryker, and Bristol-Myers Squibb Organogenesis Stratus Technologies accounting experience General Counsel & Harvard Medical since 2014 with large local public Secretary of pSivida School accounting firms Corp. with earlier 18

years at career at McDermott, Organogenesis; also Will & Emery served as COO and CFO Recognized as one of Ernst & Young's 2009 "Entrepreneur of the Year" Innovative Clinical Solutions 4 Background Information

Name/Title4 Experienced Leadership with Track Record of Execution Henry Hagopian Gary Gillheeney, Sr Patrick Bilbo Brian Grow Antonio Montecalvo Lori Freedman Interim Chief Financial President & Chief Chief Operating Chief Commercial VP, Health

Policy VP and Officer, VP Finance, Executive Officer Officer Officer and Contracting General Counsel Treasurer 25+ years in senior 13 years at 26 years with 16 years with 17 years with 15+ years as